Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Titel:
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Auteur:
Jaeger, Hans Overton, Edgar T Richmond, Gary Rizzardini, Giuliano Andrade-Villanueva, Jaime Federico Mngqibisa, Rosie Hermida, Antonio Ocampo Thalme, Anders Belonosova, Elena Ajana, Faïza Benn, Paul D Wang, Yuanyuan Hudson, Krischan J Español, Carlos Martín Ford, Susan L Crauwels, Herta Margolis, David A Talarico, Christine L Smith, Kimberly Y van Eygen, Veerle Van Solingen-Ristea, Rodica Vanveggel, Simon Spreen, William R